NO20032771L - Farmasöytisk preparat som omfatter tienopyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner eller prostaglandinderivater (2) - Google Patents

Farmasöytisk preparat som omfatter tienopyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner eller prostaglandinderivater (2)

Info

Publication number
NO20032771L
NO20032771L NO20032771A NO20032771A NO20032771L NO 20032771 L NO20032771 L NO 20032771L NO 20032771 A NO20032771 A NO 20032771A NO 20032771 A NO20032771 A NO 20032771A NO 20032771 L NO20032771 L NO 20032771L
Authority
NO
Norway
Prior art keywords
thienopyrimidines
antithrombotics
prostaglandins
pharmaceuticals
calcium antagonists
Prior art date
Application number
NO20032771A
Other languages
English (en)
Other versions
NO20032771D0 (no
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10063221A external-priority patent/DE10063221A1/de
Priority claimed from DE2000163884 external-priority patent/DE10063884A1/de
Priority claimed from DE2000164991 external-priority patent/DE10064991A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20032771D0 publication Critical patent/NO20032771D0/no
Publication of NO20032771L publication Critical patent/NO20032771L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Farmasøytisk preparat som omfatter minst én forbindelse med formel (I). hvorR\R2ogX er som definert i krav 2, og fysiologisk akseptable salter og/eller solvater derav, og a) minst ett antitrombotikum eller b) minst én kalsiumantagonist eller c) minst ett prostaglandin eller prostaglandinderivat, til fremstilling av et medikament for behandling av angina, høyt blodtrykk, pulmonal hypertensjon, kongestiv hjertesvikt (CHF), kronisk, obstruktiv, pulmonal sykdom (COPD), cor pulmonale, dekstrohjerteinsuffisiens, aterosklerose, tilstander med redusert åpenhet i hjertekar, perifere karsykdommer, slag, bronkitt, allergisk astma, kronisk astma, allergisk rhinitt, glaukom, irritabel tarm-syndrom, tumorer, nyreinsuffisiens, levercirrhose og til behandling av kvinnelige seksualforstyrrelser.
NO20032771A 2000-12-19 2003-06-18 Farmasöytisk preparat som omfatter tienopyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner eller prostaglandinderivater (2) NO20032771L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10063221A DE10063221A1 (de) 2000-12-19 2000-12-19 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Antithrombotica (2)
DE2000163884 DE10063884A1 (de) 2000-12-21 2000-12-21 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Calcium-Antagonisten (2)
DE2000164991 DE10064991A1 (de) 2000-12-23 2000-12-23 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Prostaglandine oder Prostaglandinderivate (2)
PCT/EP2001/013913 WO2002049649A2 (de) 2000-12-19 2001-11-28 Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate (2)

Publications (2)

Publication Number Publication Date
NO20032771D0 NO20032771D0 (no) 2003-06-18
NO20032771L true NO20032771L (no) 2003-06-18

Family

ID=27214206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032771A NO20032771L (no) 2000-12-19 2003-06-18 Farmasöytisk preparat som omfatter tienopyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner eller prostaglandinderivater (2)

Country Status (16)

Country Link
US (1) US20040058940A1 (no)
EP (1) EP1347762A2 (no)
JP (1) JP2004516268A (no)
KR (1) KR20030059350A (no)
CN (1) CN1481243A (no)
AR (1) AR035675A1 (no)
AU (1) AU2002226362A1 (no)
BR (1) BR0116247A (no)
CA (1) CA2431147A1 (no)
CZ (1) CZ20031722A3 (no)
HU (1) HUP0401368A2 (no)
MX (1) MXPA03005441A (no)
NO (1) NO20032771L (no)
PL (1) PL361812A1 (no)
SK (1) SK8032003A3 (no)
WO (1) WO2002049649A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107394A1 (en) * 2001-12-17 2005-05-19 Ardeschir Ghofrani Novel use of selective pde5 inhibitors
ES2441958T3 (es) * 2006-07-11 2014-02-07 Janssen Pharmaceutica Nv Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4
US20200009105A1 (en) * 2017-02-28 2020-01-09 Vanderbilt University Prostacyclin, prostacyclin analogs, and methods of treating or preventing rejection of solid organ transplants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
JPS5459266A (en) * 1977-10-14 1979-05-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analogs and their preparation
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2672601B1 (fr) * 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
AU734734B2 (en) * 1997-10-28 2001-06-21 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
DE19943815A1 (de) * 1999-09-14 2001-03-15 Merck Patent Gmbh Verwendung von Thienopyrimidinen

Also Published As

Publication number Publication date
JP2004516268A (ja) 2004-06-03
HUP0401368A2 (hu) 2004-10-28
WO2002049649A2 (de) 2002-06-27
WO2002049649A3 (de) 2002-11-21
AR035675A1 (es) 2004-06-23
CZ20031722A3 (cs) 2003-09-17
AU2002226362A1 (en) 2002-07-01
BR0116247A (pt) 2003-11-04
NO20032771D0 (no) 2003-06-18
MXPA03005441A (es) 2003-09-10
KR20030059350A (ko) 2003-07-07
US20040058940A1 (en) 2004-03-25
SK8032003A3 (en) 2003-11-04
CN1481243A (zh) 2004-03-10
PL361812A1 (en) 2004-10-04
EP1347762A2 (de) 2003-10-01
CA2431147A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
BR0115995A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
ATE520694T1 (de) A2b-adenosinrezeptorantagonisten
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
IS6444A (is) Pýrimidín karboxamíð nytsamleg sem latar á PDE4 samsætuensím
PE20020856A1 (es) 1,2,3,4-tetrahidronaftil aminas aciladas
WO2002041896A3 (de) Verwendung von thienopyrimidinen
DE60216094D1 (de) Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)
CN1057051A (zh) 羟基和烷氧基吡啶衍生物
CA2487365A1 (en) Piperidine derivatives as potassium channel blockers
DE602004018808D1 (de) Antagonisten des a2b-adenosinrezeptors
HU196597B (en) Process for producing benzimidazole derivatives, imidazo/4,5-b/pyridine derivatives and pharmaceutics comprising such compounds
MXPA05008581A (es) Derivados de sulfonamida como moduladores de ppar.
WO2004041806A3 (en) Substituted 4-amino-1-(pyridylmethyl) piperidine as muscarinic receptor antagonists
WO2003011849A8 (en) Process for the production of beraprost and its salts
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
BR0116255A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)
KR20010085852A (ko) 2,3-이치환 피리딘 유도체, 그의 제조방법, 그를 함유하는의약 조성물, 및 그의 제조용 중간체
NO20053715L (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk
WO2007014008A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2002049649A3 (de) Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate (2)
CN101495451B (zh) (s)-(-)-氨氯地平樟脑磺酸盐或其水合物及包含其的药物组合物
WO2000058300A1 (en) Chroman derivatives
NO983831D0 (no) Nye substituerte N-metyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
NO20053581L (no) Optisk aktivt dihydropyridinderivat.